Arcturus Slumps Amid Analyst Pessimism on Vaccine

Daily Updates


Arcturus Therapeutics  (ARCT) – Get Report shares lost half their market value as three analysts cut their ratings on the biopharma after a disappointing progress report on its coronavirus vaccine candidate.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *